Kymera Therapeutics, Inc. cotiza a 114.97 USD y tiene una capitalización bursátil de $9.5B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b …
| Periodo | 2026-11 | 2026-08 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.62 | $-0.71 | $-0.98 |
| Estimado | $-1.26 | $-0.74 | $-0.86 | $-0.77 |
| Sorpresa | — | +16.2% | +17.4% | -27.3% |
| Métrica | KYMR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 0.0% | 57.0% | -57.0% |
| Operating Margin | -891.1% | -38.6% | -852.5% |
| Net Margin | -794.0% | -33.6% | -760.5% |
| FCF Margin | -597.6% | -13.9% | -583.8% |
| ROE | -19.7% | -40.4% | +20.7% |
| ROA | -17.9% | -32.0% | +14.1% |
| Current Ratio | 10.47 | 2.84 | +7.63 |
| Debt / Equity | — | 0.28 | — |